AU4977896A - Immunotherapy screening, prognosis, and treatment methods and compositions - Google Patents

Immunotherapy screening, prognosis, and treatment methods and compositions

Info

Publication number
AU4977896A
AU4977896A AU49778/96A AU4977896A AU4977896A AU 4977896 A AU4977896 A AU 4977896A AU 49778/96 A AU49778/96 A AU 49778/96A AU 4977896 A AU4977896 A AU 4977896A AU 4977896 A AU4977896 A AU 4977896A
Authority
AU
Australia
Prior art keywords
prognosis
compositions
treatment methods
immunotherapy
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49778/96A
Inventor
Avi Eisenthal
Amnon Gonenne
Meir Shinitzky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMMUNOTHERAPY Inc
Original Assignee
IMMUNOTHERAPY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMMUNOTHERAPY Inc filed Critical IMMUNOTHERAPY Inc
Publication of AU4977896A publication Critical patent/AU4977896A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU49778/96A 1995-02-17 1996-02-12 Immunotherapy screening, prognosis, and treatment methods and compositions Abandoned AU4977896A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39255395A 1995-02-17 1995-02-17
US392553 1995-02-17
US48185795A 1995-06-07 1995-06-07
US481857 1995-06-07
PCT/US1996/001876 WO1996025664A1 (en) 1995-02-17 1996-02-12 Immunotherapy screening, prognosis, and treatment methods and compositions

Publications (1)

Publication Number Publication Date
AU4977896A true AU4977896A (en) 1996-09-04

Family

ID=27013925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49778/96A Abandoned AU4977896A (en) 1995-02-17 1996-02-12 Immunotherapy screening, prognosis, and treatment methods and compositions

Country Status (3)

Country Link
AU (1) AU4977896A (en)
IL (1) IL117159A0 (en)
WO (1) WO1996025664A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1991097A (en) * 1996-03-15 1997-10-01 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
WO2000011476A1 (en) * 1998-08-25 2000-03-02 The Immune Response Corporation Methods for evaluating immune function
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2073011A1 (en) * 2007-12-20 2009-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods of processing biological samples
WO2023121362A1 (en) * 2021-12-22 2023-06-29 씨제이제일제당 (주) Antiviral composition comprising nucleoside analogues derived from nucleic acid and pharmaceutically acceptable salt thereof
KR102584927B1 (en) * 2021-12-22 2023-10-06 씨제이제일제당 (주) Antiviral composition comprising nucleoside analogues derived from nucleic acid or pharmaceutically acceptable salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
EP0615758B1 (en) * 1988-05-24 1999-09-22 Yeda Research And Development Co. Ltd. Anti-tumor vaccines
IT1264516B1 (en) * 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin IMMORTALIZED DENDRITIC CELLS
US5583713A (en) * 1994-07-22 1996-12-10 Analog Devices, Inc. Pipelined demodulation and ADC conversion scheme for disk drive servo system

Also Published As

Publication number Publication date
IL117159A0 (en) 1996-06-18
WO1996025664A1 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
AU694837B2 (en) Naphthyl compounds, intermediates, compositions, and methods
AU6267896A (en) Antibody and antibody fragments for inhibiting the growth oftumors
AU2582897A (en) Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AU5259398A (en) Hopper
AU5312198A (en) Screening method
AU2440997A (en) Calixpyrroles, calixpyridinopyrroles and calixpyridines
AU4052897A (en) Cancer treatment method
AU8693098A (en) Compositions and methods for treating diabetes
AU2936897A (en) Subchirp processing method
AU5757998A (en) Revolving door
AU4977896A (en) Immunotherapy screening, prognosis, and treatment methods and compositions
AU1320797A (en) Ginseng processing method and processed ginseng prepared by the same
AU5798996A (en) Adnaz, compositions and processes
AU2690897A (en) Revolving door
AU3200197A (en) New composition and methods
EP0791407A3 (en) Sifter
AU2531397A (en) Enantiomeric screening process, and compositions therefor
AUPO380996A0 (en) Scallop processing
AU6601096A (en) Dax-1 protein, methods for production and use thereof
AU5594794A (en) Immunotherapy composition and method
AU4122897A (en) Multi-resistant bacteria, methods for obtaining them and their uses
AU2550497A (en) Simplified bimodal process
AU4284397A (en) Process scheduler
AU3631795A (en) Composition and method for immunotherapy
AUPO202796A0 (en) Receival hopper